Serum cardiac troponin T (cTnT) concentrations are frequently increased in chronic dialysis patients as measured by the first-generation ELISA immunoassay, as is creatine kinase (CK) MB mass in the absence of acute ischemic heart disease. We designed this study to compare four serum markers of myocardial injury [CK-MB mass, first-generation ELISA cTnT, second-generation Enzymun cTnT, and cardiac troponin I (cTnI)] in dialysis patients without acute ischemic heart disease. We also evaluated skeletal muscle from dialysis patients as a potential source of serum cTnT. No patients in the clinical evaluation group (n ‫؍‬ 24) studied by history and by physical examination, electrocardiography, and twodimensional echocardiography had evidence of ischemic heart disease. Biochemical markers were measured in serial predialysis blood samples with specific monoclonal antibody-based immunoassays. For several patients at least one sample measured above the upper reference limit: CK-MB, 7 of 24 (30%); ELISA cTnT, 17 of 24 (71%); Enzymun cTnT, 3 of 18 (17%); and cTnI, 1 of 24 (4%). In a separate group of dialysis patients (n ‫؍‬ 5), expression of cTnT, but not cTnI, was demonstrated by Western blot analysis in 4 of 5 skeletal muscle biopsies. Chronic dialysis patients without acute ischemic heart disease frequently had increased serum CK-MB and cTnT. The specificity of the second-generation cTnT (Enzymun) assay was improved over that of the firstgeneration (ELISA) assay; cTnI was the most specific of the currently available biochemical markers. cTnT, but not cTnI, was expressed in the skeletal muscle of dialysis patients.
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The biochemical diagnosis of acute myocardial infarction is difficult in patients with chronic renal failure because of frequent false-positive increases of creatine kinase (CK)-MB [1] [2] [3] [4] [5] [6] [7] . 3 The contractile proteins, cardiac troponin T (cTnT) and cardiac troponin I (cTnI), are rapidly becoming part of the clinical criteria for the detection of myocardial injury [8 -10] . cTnI has not been demonstrated in skeletal muscle under any developmental or disease stimuli [11] . By contrast, cTnT is reexpressed in denervated and regenerating rat skeletal muscle [12] and in skeletal muscle obtained from patients with Duchenne muscular dystrophy and polymyositis [13] and is increased in sera from patients with chronic myopathies and rhabdomyolysis [14 -16] . Unexplained increases of both serum cTnT [17] [18] [19] [20] [21] [22] and CK-MB [1] [2] [3] in chronic dialysis patients have raised questions about the cardiac specificity of both markers in this population. In addition the first-generation ELISA (Boehringer Mannheim) for cTnT has a 3.6% cross-reactivity with skeletal muscle troponin [23] . The new second-generation Enzymun assay (Boehringer Mannheim) for cTnT shows no cross-reactivity [24] . We compared serum CK-MB mass, cTnT (measured by both assays), and cTnI in 24 dialysis patients without acute ischemic heart disease and evaluated skeletal muscle as a potential source of the increased serum cTnT in a separate group of 5 patients with chronic renal failure.
Materials and Methods
This study was approved by the Human Subjects Research Committee of the participating institution.
cardiac evaluation group
Twenty-four patients were chosen from seven dialysis centers from within the metropolitan area if they had no history of acute heart disease and no regional wall motion abnormalities on a preenrollment echocardiogram or multigated acquisition scan. After informed consent, patients underwent history and physical examination, 12-lead electrocardiography, two-dimensional echocardiography, and serial biochemical sampling for total CK, CK-MB mass, cTnT, cTnI, blood urea nitrogen (BUN), and creatinine. Within 10 days of biochemical sampling, the first three parts of the cardiac evaluation were completed. These studies were performed on the same day and interpreted by practitioners blinded to the patient's biochemical data. We evaluated 19 patients in the outpatient setting and another 5 patients during a hospitalization for noncardiac illness. M-mode echocardiogram measurements were made of left ventricular (LV) posterior wall thickness (normal reference range, 6 -11 mm) and intraventricular septal thickness (normal reference range, 6 -13 mm) [25] . LV mass (normal reference range, 102-287 g) was calculated by the method of Troy et al. [26] . Blood samples were obtained immediately before the dialysis procedure. All patients were dialyzed three times per week on Monday-Wednesday-Friday or Tuesday-Thursday-Saturday. A sample was obtained for each patient on at least 2 consecutive dialysis days. In follow-up telephone interviews Ն6 months after the initial evaluation, histories were updated to include subsequent hospitalizations or evaluations related to cardiovascular disease. Two of the 24 patients were lost to follow-up.
skeletal muscle biopsy group
The five patients with chronic renal failure in the biopsy study had biochemical sampling for total CK, CK-MB mass, cTnT, cTnI, BUN, and creatinine. Skeletal muscle biopsies were taken from the brachial radialis muscle at the time of hemodialysis vascular access placement in three patients. The external oblique muscle was biopsied at the time of renal transplantation in two patients. Serum samples were obtained before biopsy.
serum biochemical markers
Blood samples were collected in evacuated tubes and centrifuged immediately; sera were frozen at Ϫ40°C until all were collected. Total CK activity (reference values: men, Յ300 U/L; women, Յ200 U/L) was measured at 37°C on an Ektachem 700 RX with a kinetic enzymatic method (Johnson & Johnson, Rochester, NY). The lower limit of detection was 20 U/L [27] . CK-MB (reference value, Յ5 g/L) was measured by a mass immunoassay based on a monoclonal antibody that recognizes CK-MB, but neither CK-MM nor CK-BB, on the Stratus II Analyzer (Dade International, Miami, FL) [27] . The proportion of CK-MB to total CK was calculated as: % CK-MB ϭ (CK-MB/total CK) ϫ 100 (reference value, Յ2.5%) [27] .
cTnT (reference value, Յ0.2 g/L) was quantified by a first-generation commercial ELISA on the ES300 (CardiAC Troponin T; Boehringer Mannheim, Indianapolis, IN) [27] , using streptavidin-coated tubes and two anticTnT antibodies. The capture antibody (designated M7) is specific toward cTnT, but the horseradish peroxidaselabeled second antibody (1B10) has ϳ10% cross-reactivity with skeletal muscle troponin T, resulting in 2-4% assay cross-reactivity with skeletal TnT. cTnT was also quantified by a second-generation immunoassay, which uses the same capture antibody (M7) and a detection antibody (M11.7) (Enzymun, ES300; Boehringer Mannheim) that shows no cross-reactivity with skeletal troponin T concentrations as much as 1000 g/L (Ͻ0.005%) [24] . The lower limit of detection for both cTnT assays was 0.02 g/L. In only 18 of 24 of the study subjects were enough patient sera available for reanalysis by the Enzymun assay.
cTnI (reference value, Յ0.8 g/L) was measured by the prototype immunoassay and the Food and Drug Administration-approved immunoassay (Stratus II; Dade International) with the same two cTnI-specific monoclonal antibodies as capture and labeled antibody. The specificity of the antibodies [28] and the analytical performances of the prototype [11] and production immunoassays [29] have previously been reported. The detection limit in serum of this immunoassay was 0.35 g/L.
western blots
Biopsies were frozen immediately after collection and stored at Ϫ80°C until homogenized. Western blots were completed for cTnI and cTnT. Frozen tissue (40 -60 mg of healthy human myocardium, and healthy and diseased skeletal muscle) was homogenized in 1 mL of potassium phosphate buffer [200 mmol/L K 2 HPO 4 , 5 mmol/L ethyleneglycol-bis-(␤-aminoethyl ether)-N,N,NЈ,N-tetraacetic acid, 5 mmol/L ␤-mercaptoethanol, 100 mL/L glycerol, pH 7.4] in a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). The homogenates were incubated at ambient temperature for 1 h and then centrifuged at 40 000 ϫ g for 30 min. The total protein concentration was determined by a modified Lowry method [30] (Sigma Diagnostics, St. Louis, MO). Then 50 g of total protein from each homogenate were separated on two identical 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis minigels for 1 h at 150 V on a MiniProtean electrophoresis apparatus (Bio-Rad, Hercules, CA). After electrophoresis, the proteins were transferred (Mini TransBlot electrophoresis transfer apparatus; Bio-Rad) to nitrocellulose membranes in the cold for 1 h at 100 V in transfer buffer (25 [31] ; Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France)] diluted to 2 g/mL in 10 g/L dry milk in TTBS. (Note: The monoclonal anti-cTnT antibody, derived from hybridization of BALB/c mouse splenic B cells immunized with human cTnT and myeloma line sp 2/0, exhibited minor crossreactivity with some human skeletal muscle troponin T isoforms, according to Lakeland Biomedical). The membranes were washed three times in TTBS and incubated for 1 h with a 1:3000 dilution of the secondary horseradish peroxidase-labeled anti-mouse Ig antibody (Amersham, Arlington Heights, IL). The membranes were again washed three times in TTBS before a 1-min incubation with the chemiluminescent substrate (ECL; Amersham). The substrate was drained off, and the membranes were placed in a sealed plastic bag and exposed to x-ray film (Fuji Rx; Fisher Scientific, Chicago, IL) for 1 min. Commercially prepared molecular mass calibrators (Bio-Rad) and purified cTnT, cTnI, fast skeletal TnT, and skeletal TnI (a gift from Spectral Diagnostics, Toronto, Canada) were included in each run. The blot was imaged on a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA).
statistical analysis
Continuous variables were reported as means and ranges. Analysis of variance was used for comparing repeated measures of cTnI, cTnT, total CK, and CK-MB. Simple regression was used to analyze the relationships between CK-MB and cTnI, CK-MB and cTnT, and first-and secondgeneration cTnT assay results. Statistical significance was defined as P Ͻ0.05.
Results
For 12 months, cardiac status was evaluated for 24 chronic dialysis patients, and skeletal muscle evaluations were completed on 5 chronic renal failure patients. Data for each patient group are presented separately.
clinical evaluation group
The mean patient age was 49 years (range 30 -73 years), and 75% were male. Renal failure was caused by diabetes in 11 (46%) patients and by chronic glomerulonephritis (n ϭ 3), polycystic kidney disease (n ϭ 1), hypertensive nephrosclerosis (n ϭ 6), focal glomerulosclerosis (n ϭ 2), and poststreptococcal glomerulonephritis (n ϭ 1). Patients had been on dialysis for an average of 2 years (1-4 years). In addition to diabetes, risk factors for cardiovascular disease included hypertension in 92%, hyperlipidemia in 26%, tobacco use in 33%, and a positive family history in 12% of patients. Their medications included erythropoietin, antihypertensives, insulin, vitamins, and lipid-lowering drugs. Clinical histories did not show past or current cardiac injury. Mean blood pressures were 152 mm Hg (96 -204 mm Hg) systolic and 83 mm Hg (65-120 mm Hg) diastolic. By cardiac examination, 15 patients were apparently healthy; 9 patients had a systolic murmur and 3 of these had a fourth heart sound. No patient had a pericardial friction rub or congestive heart failure.
Electrocardiograms completed within 10 days of biochemical sampling exhibited apparently healthy sinus rhythm (n ϭ 24), LV hypertrophy (n ϭ 14), and nonspecific ST and T wave changes (n ϭ 9). Echocardiograms from this time demonstrated apparently healthy LV systolic function (n ϭ 22) and mildly decreased LV function (n ϭ 2). Two patients had small pericardial effusions. None had a regional wall-motion abnormality. LV hypertrophy was present in 21 patients. Mean LV M-mode echocardiogram measurements were: diastolic posterior wall thickness, 13 mm (9 -18 mm); diastolic septal thickness, 17 mm (11-18 mm); mass, 397 g (277-499 g).
Follow-up telephone interviews were completed with 22 patients between 6 and 8 months after biochemical sampling. Four patients had undergone renal transplantation. No patient had a history of cardiovascular symptoms, evaluations, or hospitalizations. In the two patients who were not interviewed, concentrations of CK-MB, cTnT, and cTnI were normal.
biochemical data
Three consecutive serum samples were obtained from 19 patients, and 2 consecutive samples were obtained from 5 patients for a total of 67 samples. Variations were not statistically significant during the sampling days for any biochemical markers. The mean total CK for all samples was 107 (20 -399) U/L. A total CK measurement exceeding the upper reference limit (Ն300 U/L for men) was observed in one patient. The mean CK-MB mass for all 67 samples was 3.6 (0 -17.2) g/L. At least one sample had increased CK-MB in 7 of 24 (30%) patients (Fig. 1) ; 16 of 19 (84%) samples measured above the normal reference range. The mean CK-MB percentage for all samples was 4.5% (0 -32%). In 13 of 24 (54%) patients (Fig. 1) , CK-MB percentages for 32 of 62 (52%) samples were above the normal reference range.
The mean ELISA cTnT for all samples was 0.6 (0 -3.49) g/L. For 17 of 24 (71%) patients in whom serum cTnT was measured by the first-generation (ELISA) assay, cTnT concentrations were increased (Fig. 1 ) in 38 of 67 (57%) samples. The mean cTnI for all samples was 0.6 (0 -13.2) g/L. A single patient had an increased cTnI concentration for all three measurements (Fig. 1 ). An additional 10 predialysis samples for this patient obtained during a 4-month period revealed chronic increases of CK-MB (mean, 5.4; range, 5.1-5.9 g/L), ELISA cTnT (mean, 2.8; range, 2.75-3.12 g/L), and cTnI (mean, 11.0; range, 9.2-12.9 g/L). In a complete reevaluation at 6 months follow-up, results were unchanged from the initial evaluation.
For the 18 patients with sufficient residual volume for analysis, the mean Enzymun cTnT was 0.18 (0.01-2.18) g/L, and in 3 (17%) of these patients cTnT concentrations were above-normal in both cTnT assays (Fig. 1) . Enzymun cTnT concentrations in these 3 patients were increased in 8 of 49 (16.3%) samples. There was no significant correlation between ELISA cTnT and Enzymun cTnT (r ϭ 0.185; P ϭ 0.21). Only in patient 13 (all three specimens) were cTnI concentrations increased over those of the 18 patients studied for comparison, but the Enzymun cTnT concentration was normal for all three samples. Overall, the Enzymun cTnT assay exhibited an approximately threefold increase in potential false-positive results compared with cTnI (16.3% vs 5.6%, respectively) in these 18 patients.
The mean BUN for all 67 samples was 640 mg/L (340 -970 mg/L) and the mean creatinine was 110 mg/L (50 -190 mg/L). The highest BUN and creatinine for a given patient was often observed on Monday or Tuesday, the day after the longest hiatus between dialysis assays. There was no significant correlation between the higher BUN or creatinine and the increase of any serum cardiac markers.
skeletal muscle biopsy group
Clinical data for the five patients who underwent skeletal muscle biopsy are presented in Table 1 . All patients were receiving chronic hemodialysis or had recently begun hemodialysis treatment. Four of the five patients had hypertension, two had diabetes, and one (Fig. 2, lane 4) had a history of coronary artery disease with percutaneous coronary angioplasty of the right coronary artery. No patient in this group had myocardial ischemia at the time of biochemical sampling. For these 5 patients, 1 of 5 had an increased CK-MB mass, 2 of 5 had an increased ELISA cTnT concentration, 0 of 5 had an increased Enzymun cTnT concentration, and 0 of 5 had an increased cTnI concentration. As shown in Fig. 2A , Western blot analysis expressed a single isoform of cTnT (M r 41 kDa) for 4 of 5 skeletal muscles (lanes 4, 5, 7, and 9) comigrating with both cTnT expressed in the human heart (lane 3) and the cTnT standard (lane 6). Bands of lower M r (36 -38 kDa) are skeletal isoforms of TnT, made visible by the slight cross-reactivity of the JS-2 antibody at high concentrations Fig. 1 . Serum biochemical markers of 24 chronic dialysis patients without acute ischemic heart disease.
Shaded areas below the upper reference limits are the number of samples of 67 total that were in the normal reference range. Circles are individual samples that were above normal. Numbers in balls reflect individual patients. (Fig. 2B) , cTnI expression was not detectable in the 5 renal patients' skeletal muscle or in apparently healthy skeletal muscle. Further, the 11E12 anti-cTnI antibody showed no cross-reactivity for either skeletal troponin I or skeletal troponin T (lane 1).
Discussion
Patients with chronic renal failure and receiving hemodialysis are a high risk group for cardiovascular disease. Hypertension and diabetes are independent risk factors for cardiovascular disease [32] and were the cause of renal failure in 17 of 24 (71%) of the patients in this study. Accelerated atherosclerosis is associated with chronic hemodialysis [33] , and more than one-half of the deaths in dialysis patients are of cardiovascular etiology [34] . Therefore, one must assign reliable markers for the presence of myocardial injury and for assessment of the risk of cardiovascular events in these patients.
Our findings are consistent with those of Jaffe et al. [1] , Chan et al. [2] , and Lal et al. [3] , who have demonstrated false elevations of CK-MB in chronic dialysis patients without acute ischemic heart disease. Chronic dialysis is associated with abnormal protein metabolism and muscle wasting [35] . This may be the source of elevated CK-MB in these patients [1] . Our observations also support those of earlier investigators who demonstrated frequent elevation of cTnT measured by the first-generation ELISA in chronic dialysis patients [17] [18] [19] [20] . Although the ELISA may give falsely elevated cTnT values caused by nonspecific binding, another potential source of the elevated cTnT may be the cross-reactivity with skeletal troponin T in the first-generation (ELISA) assays. We found fewer false elevations of cTnT with the second-generation (Enzymun) assay. This improved specificity of the Enzymun assay has also been reported by Braun et al. [36] . Our 6-month follow-up telephone interviews revealed no heart disease in this study group, most likely because the population studied was a highly selected, younger patient group, selected because of the absence of ischemic heart disease. One patient exhibited unexplained increases of serum cTnI concentrations. Although this cTnI increase was possibly an analytical false-positive result, increased serum cTnI concentrations in this patient (Fig. 1, patient  13) , as measured by the Stratus II analyzer, were also confirmed by an alternative immunoassay system (Behring Opus) that uses different anti-cTnI antibodies [37] . Patient 13 had no evidence of LV hypertrophy, valvular heart disease, or pericardial disease. His LV systolic and diastolic functions were normal.
In the second part of the study, we have demonstrated expression of cTnT in skeletal muscle in four of five renal failure patients biopsied. This finding was consistent with reexpression of cTnT isoforms identified in failing hearts [38] . The mechanism for expression of cTnT in skeletal muscle from renal failure patients is likely associated with the peripheral myopathy associated with renal disease [35] . Expression of cTnT in diseased or regenerating skeletal muscle appears to represent reexpression of a fetal gene, given that fetal skeletal muscle expresses cTnT [12] . Previous studies have demonstrated a reexpression of cTnT isoforms in regenerating rat skeletal muscle [12] and in skeletal muscle from patients with Duchenne muscular dystrophy and polymyositis [13] . In light of these studies, our findings implicate skeletal muscle as a possible source of abnormally elevated serum cTnT in this population. It would be informative to perform the Western blot experiments with the M7 monoclonal antibody, which was reported by Katus et al. [23] to have absolute specificity for cTnT, if the antibody should become available for general experimentation. The absence of cTnI in skeletal muscle from the patients appears to reflect its superior tissue specificity, as described by Bodor et al. [11] .
This study involved a relatively small number of patients, but the findings are compelling. Preenrollment Apparently healthy heart and skeletal muscle are included as controls. Tissue homogenates were electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide minigel, transferred onto nitrocellulose, and hybridized with either JS-2 monoclonal anti-cTnT (A) or 11E12 monoclonal anti-cTnI (B) primary antibodies and an anti-mouse Ig horseradish peroxidase-labeled second antibody. Lane 1, skeletal troponins I and T (2 g each); lane 2, apparently healthy skeletal muscle homogenate (50 g); lane 3, apparently healthy heart homogenate (25 g); lanes 4 -5 and 7-9, skeletal muscle homogenates from renal failure patients (50 g); lane 6, purified cTnT or cTnI. Positions of the molecular mass standards are shown on the left. echocardiograms for two patients showed mildly decreased LV function. These patients had echo evidence of hypertensive heart disease. Both patients' echocardiograms were unchanged at the time of biochemical sampling and both had unremarkable measurements for all biochemical markers, with the exception of a single elevated cTnT concentration (ELISA). This study was limited to patients without acute myocardial injury. The clinical performance of these markers in dialysis patients with acute myocardial injury is unknown. An alternative anticTnT antibody was used for Western blot analysis rather than the anti-cTnT antibodies used in the ELISA and Enzymun immunoassays.
In conclusion, patients maintained on chronic dialysis without evidence of acute myocardial injury often have chronically increased CK-MB mass and cTnT concentrations. The second-generation cTnT (Enzymun) assay has better specificity than the first-generation (ELISA) assay for dialysis patients without acute ischemic heart disease. Only a single patient, who had no clinical evidence of myocardial injury, exhibited an increased serum cTnI. cTnT, but not cTnI, was expressed in the skeletal muscle of chronic renal failure patients. Thus, cTnI appears to be a superior marker of cardiac injury in the chronic dialysis population.
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